P202 Real life experience with mepolizumab and comparison with omalizumab in children with severe asthma

the one type-2 biomarker frequency-weighted in and respectively. contrast, the 814 patients with both biomarkers low at baseline had observed vs predicted rate ratios of 0.86 vs 1.00; the corresponding percentages reduction in asthma attacks were 14% and 0%, respectively. The relative risk associated with biomarkers was consistent across populations, but the absolute risk and the treatment benefit conferred by type-2 biomarkers was greater in a population at higher background risk. The prototype ORACLE scale predicts the excess risk conferred by raised biomarkers which is removed by anti-inflammatory therapy in trial populations. for large-scale paediatric mepolizumab studies, especially given evidence of low Type-2 cytokines in children with severe asthma.